title: A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
authors.affiliation: Department of PMR, Division of Rheumatology, Erciyes University, Faculty of Medicine, Kayseri, Turkey, ozgur.akgul.md@gmail.com.
authors.forename: Özgür
authors.initials: Ö
authors.lastname: Akgül
authors.forename: Gamze
authors.initials: G
authors.lastname: Kılıç
authors.forename: Erkan
authors.initials: E
authors.lastname: Kılıç
authors.forename: İsa
authors.initials: İ
authors.lastname: Cüce
authors.forename: Salih
authors.initials: S
authors.lastname: Özgöçmen
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000175:diagnosis; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D028761:Withholding Treatment
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept